Cargando…
Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs
Peritoneal carcinomatosis still lacks reliable therapeutic options. We aimed at testing a drug delivery strategy allowing a controlled release of cytotoxic molecules and selective targeting of tumor cells. We comparatively assessed the efficacy of a loco-regional intraperitoneal treatment in immunoc...
Autores principales: | Montagner, Isabella Monia, Merlo, Anna, Zuccolotto, Gaia, Renier, Davide, Campisi, Monica, Pasut, Gianfranco, Zanovello, Paola, Rosato, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226476/ https://www.ncbi.nlm.nih.gov/pubmed/25383653 http://dx.doi.org/10.1371/journal.pone.0112240 |
Ejemplares similares
-
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
por: Montagner, Isabella Monia, et al.
Publicado: (2015) -
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models
por: Zuccolotto, Gaia, et al.
Publicado: (2014) -
Hyaluronan-binding peptide for targeting peritoneal carcinomatosis
por: Ikemoto, Hideki, et al.
Publicado: (2017) -
Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines
por: Dalla Pietà, Anna, et al.
Publicado: (2021) -
PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)